A new analysis of data from the SURPASS program indicates that the use of tirzepatide (Mounjaro) can help people with diabetic Reach your blood sugar goals in a fraction of the time with other medications.
The results of the analysis, presented at the annual meeting of the European Association for the Study of Diabetes (EASD), indicate that adults with type 2 diabetes who received a weekly injection of tirzepatide helped patients reach glycemic goals 4-12 weeks earlier than Those receiving semaglutide 1 mg and long-acting insulin degludec.
“Tirzepatide is unique in that it mimics two natural insulin-secreting and appetite-suppressing hormones in a single injection,” said lead researcher Adie Viljoen, MD, a consultant metabolic physician and chemist from the East and North Hertfordshire Trust in the United Kingdom. Present. “The speed we observe in lowering glucose and losing weight is beyond anything else we currently have and may put adults with type 2 diabetes in a better position to prevent long-term complications. But it is important to remember that these medications should be used in addition to diet and exercise. .”
with Approval of Eli Lilly’s GIP/GLP-1 dual novelwhich occurred in May 2022, based on the results of the SURPASS program, multiple analyzes have been performed since the release of the initial data providing more information on the effects of tirzepatide at different doses and against different comparisons. Available in American pharmacies Beginning in June 2022, this drug has been adopted as a potential form therapy with significant benefits for both diabetes and obesity. In the current study, which was a pre-planned exploratory analysis, the researchers made use of data from the SURPASS-2 and -3 trials to assess time to achieve glycemic goals. This was evaluated using the Kaplan-Meier method and the hazard ratios were calculated using the Cox proportional hazards model.
In the comprehensive SURPASS-2 trial, use of tirzepatide was compared with that of semaglutide 1.0 mg. Study results suggested that tirzepatide use was associated with greater improvements in HbA1c from baseline and the proportion of subjects who reached HbA1c goals at 40 weeks. In the SURPASS-3 trial, the use of tirzepatide was compared with titrated insulin degludec. Study results indicated that tirzepatide use was associated with greater improvements in HbA1c change from baseline and the proportion of patients who reached HbA1c at 52 weeks.
In the current analyses, preliminary results indicated that tirzepatide use was associated with a significantly faster time to reach HbA1c levels of 7% or less and 6.5% or less. The median time to achieve an HbA1c of 7% or less was 8.1 weeks across all tirzepatide doses compared to 12 weeks for semaglutide and 12.1 weeks for titrated insulin degludec. The median time to achieve an HbA1c of 6.5% or less was 12.1 weeks across all tirzepatide doses, 15.7 weeks with semaglutide 1.0 mg, and 24.1 weeks with titrated insulin degludec. In weight loss analyses, results indicated that tirzepatide was associated with a faster time to achieve a 5% change in body weight compared to semaglutide 1.0, with those receiving tirzepatide achieving this in a median of 12 weeks when using tirzepatide at 10 or 15 mg compared to 24 weeks with semaglutide.
“Even a small weight loss of 5% of initial body weight is associated with clinically significant improvements in weight-related health problems for many individuals,” Viljoen added in the aforementioned statement. “For people with type 2 diabetes, their ability to achieve these improvements in health in about half the time is incredible.”
This study, “Patients with type 2 diabetes reach glycemic goals faster with tirzepatide compared with semaglutide and titrated insulin degludec,” was presented in EASD.